EVOK
Price
$4.43
Change
-$0.16 (-3.49%)
Updated
Jul 25 closing price
Capitalization
5.17M
NBIX
Price
$132.14
Change
+$0.50 (+0.38%)
Updated
Jul 25 closing price
Capitalization
13.72B
4 days until earnings call
Interact to see
Advertisement

EVOK vs NBIX

Header iconEVOK vs NBIX Comparison
Open Charts EVOK vs NBIXBanner chart's image
Evoke Pharma
Price$4.43
Change-$0.16 (-3.49%)
Volume$56.91K
Capitalization5.17M
Neurocrine Biosciences
Price$132.14
Change+$0.50 (+0.38%)
Volume$1.26M
Capitalization13.72B
EVOK vs NBIX Comparison Chart in %
Loading...
EVOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EVOK vs. NBIX commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVOK is a Hold and NBIX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (EVOK: $4.43 vs. NBIX: $132.14)
Brand notoriety: EVOK and NBIX are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EVOK: 2% vs. NBIX: 145%
Market capitalization -- EVOK: $5.17M vs. NBIX: $13.72B
EVOK [@Pharmaceuticals: Other] is valued at $5.17M. NBIX’s [@Pharmaceuticals: Other] market capitalization is $13.72B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVOK’s FA Score shows that 0 FA rating(s) are green whileNBIX’s FA Score has 0 green FA rating(s).

  • EVOK’s FA Score: 0 green, 5 red.
  • NBIX’s FA Score: 0 green, 5 red.
According to our system of comparison, EVOK is a better buy in the long-term than NBIX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVOK’s TA Score shows that 4 TA indicator(s) are bullish while NBIX’s TA Score has 4 bullish TA indicator(s).

  • EVOK’s TA Score: 4 bullish, 6 bearish.
  • NBIX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NBIX is a better buy in the short-term than EVOK.

Price Growth

EVOK (@Pharmaceuticals: Other) experienced а -2.85% price change this week, while NBIX (@Pharmaceuticals: Other) price change was +0.09% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.55%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +75.03%.

Reported Earning Dates

EVOK is expected to report earnings on May 13, 2025.

NBIX is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+3.55% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($13.7B) has a higher market cap than EVOK($5.17M). EVOK YTD gains are higher at: 0.226 vs. NBIX (-3.194). NBIX has higher annual earnings (EBITDA): 358M vs. EVOK (-7.29M). NBIX has more cash in the bank: 1.03B vs. EVOK (4.74M). EVOK has less debt than NBIX: EVOK (5M) vs NBIX (428M). NBIX has higher revenues than EVOK: NBIX (1.89B) vs EVOK (5.18M).
EVOKNBIXEVOK / NBIX
Capitalization5.17M13.7B0%
EBITDA-7.29M358M-2%
Gain YTD0.226-3.194-7%
P/E RatioN/A57.20-
Revenue5.18M1.89B0%
Total Cash4.74M1.03B0%
Total Debt5M428M1%
FUNDAMENTALS RATINGS
EVOK vs NBIX: Fundamental Ratings
EVOK
NBIX
OUTLOOK RATING
1..100
9577
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
10089
SMR RATING
1..100
9860
PRICE GROWTH RATING
1..100
3754
P/E GROWTH RATING
1..100
8238
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EVOK's Valuation (42) in the Pharmaceuticals Other industry is in the same range as NBIX (72) in the Biotechnology industry. This means that EVOK’s stock grew similarly to NBIX’s over the last 12 months.

NBIX's Profit vs Risk Rating (89) in the Biotechnology industry is in the same range as EVOK (100) in the Pharmaceuticals Other industry. This means that NBIX’s stock grew similarly to EVOK’s over the last 12 months.

NBIX's SMR Rating (60) in the Biotechnology industry is somewhat better than the same rating for EVOK (98) in the Pharmaceuticals Other industry. This means that NBIX’s stock grew somewhat faster than EVOK’s over the last 12 months.

EVOK's Price Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as NBIX (54) in the Biotechnology industry. This means that EVOK’s stock grew similarly to NBIX’s over the last 12 months.

NBIX's P/E Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for EVOK (82) in the Pharmaceuticals Other industry. This means that NBIX’s stock grew somewhat faster than EVOK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVOKNBIX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
57%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
65%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
56%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
65%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
71%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
72%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 4 days ago
72%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 6 days ago
61%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
74%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
EVOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
USSE32.780.25
+0.77%
Segall Bryant & Hamill Select Equity ETF
PTA19.880.01
+0.05%
Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund
KEUA23.89N/A
N/A
KraneShares European Carb Allw Stgy ETF
SAY25.48-0.03
-0.12%
Saratoga Investment Corp
NMS11.18-0.05
-0.48%
Nuveen Minnesota Quality Municipal Income Fund

EVOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVOK has been loosely correlated with RDHL. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if EVOK jumps, then RDHL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVOK
1D Price
Change %
EVOK100%
-3.49%
RDHL - EVOK
33%
Loosely correlated
-6.56%
RMTI - EVOK
30%
Poorly correlated
-4.46%
NBIX - EVOK
28%
Poorly correlated
+0.38%
EOLS - EVOK
26%
Poorly correlated
-1.24%
EVO - EVOK
24%
Poorly correlated
+5.19%
More